BioPorto enrolls first patient in U.S. Adult NGAL validation

BioPorto enrolled the first patient in its U.S. Adult Urine NGAL Validation Study for ProNephro AKI, targeting about 900 ICU patients across multiple sites to support a potential U.S. adult indication.